Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
9 Results for "
CSN5
" in MedChemExpress (MCE) Product Catalog:
Products (9)
9 Results for "CSN5" in MCE Product Catalog:
24
24 Cited Publications
Target:
Research Areas:
CSN5i-3 is a potent, selective and orally available inhibitor of CSN5/Jab1, and inhibits CSN-catalysed Cul1 deneddylation with an IC50 value of 5.8 nM .
Cat. No.: HY-159601
Target:
Research Areas:
CSN5-IN-1 (compound Ac-11) is an inhibitor of CSN5, with IC50 values of 12.56 μM and 19 μM as measured by FP assay and fluorescence assay, respectively. CSN5-IN-1 can also downregulate the expression of PD-L1 and upregulate the expression of NEDD8-Cul1 in cells .
Cat. No.: HY-112134A
CAS No.: 2863607-74-1
(R)-CSN5i-3 is the (R)-enantiomer of CSN5i-3. CSN5i-3 is a potent, selective and orally available inhibitor of CSN5 .
Cat. No.: HY-172252
Target:
Research Areas:
CSN5-IN-2 (Compound 31) is a CSN5 inhibitor with an IC50 of 0.36 μM. CSN5-IN-2 can increase the level of Cullin 1 neddylation, and downregulate the expression of RAD51 and PD-L1 in cancer cells. CSN5-IN-2 has anti-tumor activity, and its effect is better when combined with Talazoparib (HY-16106) .
Cat. No.: HY-181795
Target:
Research Areas:
CSN5-IN-3 (Compound 30) is a CSN5 inhibitor with an IC50 of 0.58 μM. CSN5-IN-3 inhibits the enzymatic activity of CSN5, leading to increased accumulation of NEDD8-Cul1 and promoting the degradation of PD-L1. CSN5-IN-3 downregulates Bcl-2, and upregulates P53 and Cleaved caspase-3. CSN5-IN-3 exhibits anticancer activity against triple-negative breast cancer .
Cat. No.: HY-182239
CAS No.: 2488699-00-7
Target:
Research Areas:
PDL1 degrader-3 (compound e24) is a DUBTAC-like PD-L1 degrader. PDL1 degrader-3 inhibits CSN5 enzymatic activity, increases PD-L1 ubiquitination, and induces PD-L1 degradation via the ubiquitin-proteasome pathway, reducing PD-L1 expression on tumor cell membranes. PDL1 degrader-3 blocks PD-1/PD-L1 interaction, activates the tumor immune microenvironment, enhances tumor-infiltrating T-cell immunity, and inhibits activation of immunosuppressive MDSCs and Tregs. PDL1 degrader-3 exerts antitumor effects in mouse tumor models. PDL1 degrader-3 can be used for the research of colorectal cancer, lung cancer .
Cat. No.: HY-RS03030
Target:
Research Areas:
COPS5 Human Pre-designed siRNA Set A contains three designed siRNAs for COPS5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS19669
Target:
Research Areas:
Cops5 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cops5 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
